CNS Pharmaceuticals, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CNS Pharmaceuticals, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($15.85M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($14.86M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($18.85M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($15.27M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($14.50M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($9.46M) | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | ($3.88M) | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | ($7.39M) | Mar 12, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($15.99M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($14.90M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($18.87M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($15.27M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($14.49M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($9.45M) | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | ($3.83M) | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | ($881.8K) | Mar 12, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.77M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $9.29M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $14.10M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $9.30M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $9.81M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $5.06M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | $1.85M | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $21.3K | Mar 12, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($13.81M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($17.11M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($14.14M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($10.56M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($13.54M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($7.32M) | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | ($3.55M) | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | ($716.4K) | Mar 12, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.2K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $4.2K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $3.9K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $4.4K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $5.7K | Mar 31, 2023 |
| FY2020 | Dec 31, 2020 | $17.9K | Feb 12, 2021 |
| FY2020 | Dec 31, 2019 | $20.1K | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $0 | Mar 12, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.62M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $8.70M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $1.70M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $13.05M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $8.76M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $15.85M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | $7.91M | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $683.3K | Mar 12, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.10M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $2.52M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $6.13M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $4.92M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $2.59M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.91M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | $311.0K | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $1.23M | Mar 12, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.52M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $6.18M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | ($4.43M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $8.13M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $6.16M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $13.95M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $7.60M | Mar 3, 2022 |
| FY2020 | Dec 31, 2018 | ($549.3K) | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | ($58.5K) | Mar 12, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($100.28M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($84.42M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($69.57M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($50.72M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($35.44M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($20.95M) | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | ($11.49M) | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | ($7.61M) | Mar 12, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.20M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $6.46M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $548.7K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $10.06M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $5.00M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $14.04M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | $7.24M | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $282.7K | Mar 12, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (35) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (466) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (12,509) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (11) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | (16) | Mar 31, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (35) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (466) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (12,509) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (11) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | (16) | Mar 31, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 632,516 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 117,796 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 2,486 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 1.62M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 949,052 | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 23.86M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | 16.45M | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | 12.69M | Mar 12, 2020 |